Alzheimer's drug trial results 'extremely encouraging'

“Extremely encouraging” results from a trial of a new Alzheimer’s drug sent shares of pharmaceutical company Biogen up nearly 20 percent Friday, CNBC reported.  Biogen (NASDAQ:BIIB) and Tokyo-based drugmaker Eisai reported “statistically significant” evidence that the drug, BAN2401, can slow progression of Alzheimer’s, which causes progressive mental deterioration and degeneration of the brain. The drug, developed in collaboration between Eisai and Swedish biotechnology company BioArctic,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news